arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TELA Bio, Inc.

TELA
$1.29 ▼ -0.13 (-9.12%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
36 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

TELA Bio, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $74.1M
Dividend Yield —
Revenue Growth -4.5% ↘
Op. Margin -48.1% ↗
ROIC -23.2% ↘
FCF / Share $-0.16 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -3.53
info Valuation on last close. End-of-day price, Sep 23, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.29M
↓ -4.5% —
Net Income Profit after all expenses
$-11.26M
↓ -13.5% —
Operating Margin Operating profit as % of sales
-48.1%
↑ +12.9% 6th
FCF / Share Free cash flow per share
$-0.16
↑ +16.6% —
Long-Term Debt Long-term obligations
$56.08M
— +0.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
6
Financial Health ↑
18
Cash Quality ↓
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 36 quarters